3Sutherland W H, Manning P J, de Jong S A, et al. Hormone-replacement therapy increases serum paraoxonase arylestserase activity in diabetic postmenopausal women. Metabolism, 2001,50: 319-324.
4Watson A D, Berliner J A, Hama S Y, et al. Protectire effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidased low density lipoprotein. J Clin Invest, 1995, 96:2882-2891.
5Aviram M, Rosenblat M, Bisgaier C L, et al. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest, 1998,101 : 1581-1590.
6Senti M, Tomas M, Marrugat J, et al. Paraoxonase 1192 polymorphism modilates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol, 2001, 21: 415-420.
7Josse D, Masson P. Human plsma paraoxonase. Ann Pharm Fr,2001,59 : 108- 112.
8Inoue M, Suehiro T, Nakamura T,et al. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism, 2000, 49:1400-1405.
9Pfohl M, Koch M, Enderle M D, et al. Paraoxonase 192 Gln/Arg gene polyrnorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 1999,48: 623-627.
10Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site requited for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol, 1998, 18: 1617-1624.
